Moleculomics, a Swansea university spin-out company formed in 2012, are adding the finishing touches to their flagship product Human3DProteome. To be launched later in 2017, this will for the first time, enable the high throughput screening of candidate small molecule compounds against every protein in the human body – a library of 30,000+ potential drug targets. The workflows being developed as part of this solution will provide a powerful open-ended, lead discovery environment, identifying on-target and off-target interactions across the whole proteome; detailed characterisation of active sites and millions of protein-compound interactions, involving thousands of lead compounds, screened for interaction with 1,500 drug targets of known pharmacological and therapeutic action; and a drug repurposing platform featuring all 1,600 FDA approved drugs and tens of thousands of new repurposing leads.
Isansys has created a new generation medical device - the Patient Status Engine. This is an innovative, continuous vital sign data acquisition, analysis and prediction platform that combines unobtrusive wireless wearable sensors, wireless networks, analytical algorithms and big data to provide low cost continuous, high resolution monitoring for all patients in hospital, and at home.